CERo Therapeutics Holdings, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2023 | FY2022 |
|---|---|---|---|
| Operating Activities | |||
| Net Income | $-19.9M | $-7.3M | $-667.7K |
| Depreciation & Amortization | — | — | — |
| Depreciation | — | — | — |
| Amortization | — | — | — |
| Stock-Based Compensation | — | — | — |
| Net Cash from Operating Activities | $-16.1M | $-1.5M | $-1.1M |
| Investing Activities | |||
| Capital Expenditures | — | — | — |
| Business Acquisitions | — | — | — |
| Net Cash from Investing Activities | — | $-7.9M | $180.8M |
| Financing Activities | |||
| Dividends Paid | $127.1K | — | — |
| Stock Repurchases | — | $33.5M | $139.4M |
| Net Cash from Financing Activities | — | $-32.6M | $-138.7M |
| Net Change in Cash | — | $-42.0M | $41.0M |
| Free Cash Flow | — | — | — |